Matt Niederst - Publications

Affiliations: 
2005-2011 Novartis, Basel, Basel-Stadt, France 

16 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Bunn PA, Minna J, Augustyn A, Gazdar A, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier J, et al. Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes? Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26829312 DOI: 10.1016/j.jtho.2016.01.012  0.4
2016 Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, Maruvka YE, Ji F, Bhang HC, Krishnamurthy Radhakrishna V, Siravegna G, Hu H, Raoof S, Lockerman E, Kalsy A, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nature Medicine. PMID 26828195 DOI: 10.1038/nm.4040  0.4
2016 Jia Y, Juarez J, Li J, Manuia M, Niederst MJ, Tompkins C, Timple N, Vaillancourt MT, Culazzo Pferdekamper A, Lockerman EL, Li C, Anderson J, Costa C, Liao D, Murphy E, et al. EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor. Cancer Research. PMID 26825170 DOI: 10.1158/0008-5472.CAN-15-2581  0.4
2015 Engelman JA, Oser MG, Niederst MJ, Sequist LV. Transformation from NSCLC to SCLC: when did it happen? - Authors' reply. The Lancet. Oncology. 16: e309-10. PMID 26149875 DOI: 10.1016/S1470-2045(15)00058-3  0.4
2015 Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, Sequist LV, Engelman JA. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3924-33. PMID 25964297 DOI: 10.1158/1078-0432.CCR-15-0560  0.4
2015 Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, Fulton L, Hata AN, Lockerman EL, Kalsy A, Digumarthy S, Muzikansky A, Raponi M, Garcia AR, Mulvey HE, et al. Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discovery. 5: 713-22. PMID 25934077 DOI: 10.1158/2159-8290.CD-15-0399  0.4
2015 Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. The Lancet. Oncology. 16: e165-72. PMID 25846096 DOI: 10.1016/S1470-2045(14)71180-5  0.4
2015 Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN, Moran T, Howe E, Fulton LE, Mulvey HE, Bernardo LA, Mohamoud F, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nature Communications. 6: 6377. PMID 25758528 DOI: 10.1038/ncomms7377  0.4
2014 Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, Frias RL, Gainor JF, Amzallag A, Greninger P, Lee D, Kalsy A, Gomez-Caraballo M, Elamine L, Howe E, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science (New York, N.Y.). 346: 1480-6. PMID 25394791 DOI: 10.1126/science.1254721  0.4
2014 Reyes G, Niederst M, Cohen-Katsenelson K, Stender JD, Kunkel MT, Chen M, Brognard J, Sierecki E, Gao T, Nowak DG, Trotman LC, Glass CK, Newton AC. Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output. Proceedings of the National Academy of Sciences of the United States of America. 111: E3957-65. PMID 25201979 DOI: 10.1073/pnas.1404221111  0.4
2013 Niederst MJ, Engelman JA. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Science Signaling. 6: re6. PMID 24065147 DOI: 10.1126/scisignal.2004652  0.4
2013 O'Neill AK, Niederst MJ, Newton AC. Suppression of survival signalling pathways by the phosphatase PHLPP. The Febs Journal. 280: 572-83. PMID 22340730 DOI: 10.1111/j.1742-4658.2012.08537.x  0.48
2012 O'Hayre M, Niederst M, Fecteau JF, Nguyen VM, Kipps TJ, Messmer D, Newton AC, Handel TM. Mechanisms and consequences of the loss of PHLPP1 phosphatase in chronic lymphocytic leukemia (CLL). Leukemia. 26: 1689-92. PMID 22237780 DOI: 10.1038/leu.2012.6  0.8
2011 Warfel NA, Niederst M, Newton AC. Disruption of the interface between the pleckstrin homology (PH) and kinase domains of Akt protein is sufficient for hydrophobic motif site phosphorylation in the absence of mTORC2. The Journal of Biological Chemistry. 286: 39122-9. PMID 21908613 DOI: 10.1074/jbc.M111.278747  0.8
2011 Warfel NA, Niederst M, Stevens MW, Brennan PM, Frame MC, Newton AC. Mislocalization of the E3 ligase, β-transducin repeat-containing protein 1 (β-TrCP1), in glioblastoma uncouples negative feedback between the pleckstrin homology domain leucine-rich repeat protein phosphatase 1 (PHLPP1) and Akt Journal of Biological Chemistry. 286: 19777-19788. PMID 21454620 DOI: 10.1074/jbc.M111.237081  0.8
2009 Brognard J, Niederst M, Reyes G, Warfel N, Newton AC. Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and protein kinase C. The Journal of Biological Chemistry. 284: 15215-23. PMID 19324870 DOI: 10.1074/jbc.M901468200  0.8
Show low-probability matches.